[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"protracted-bacterial-bronchitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:protracted-bacterial-bronchitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,63,99,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100634870","lung-mri-in-paediatric-lung-disease-mri-in-pbb-100634870",false,"NCT07545304","Lung MRI in Paediatric Lung Disease: MRI in PBB","Functional and Structural Imaging of the Lung Using Hyperpolarised Gas and Proton Magnetic Resonance Imaging for the Assessment of Lung Function in Paediatrics","Inclusion Criteria:\n\nMale and female children aged 5 to 17 years old\n\n* High suspicion of PBB requiring bronchoscopy\n* Be able to follow instructions\n* English speaking family member\n\nExclusion Criteria:\n\nOutside of age range\n\n* Significant learning difficulties or inability to follow instructions\n* Informed consent \u002F assent has not been provided\n* No English-speaking member of the family\n* Contraindications for MRI scanning","ALL","5 Years","17 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","Protracted bacterial bronchitis (PBB) is a problem in the lungs causing children to have a wet cough for more than 4 weeks. PBB is also known to start before and cause other lung diseases and to affect children's quality of life. It is difficult to know if a child has PBB. Listening to the lungs and measuring a child's breathing are usually normal and so a bronchoscopy (looking in the lungs with a camera) and a type of lung scan called CT are needed to diagnose PBB. These tests involve children being put to sleep under anaesthetic (bronchoscopy) or exposed to radiation (CT) and so are not performed often. PBB is difficult to treat and antibiotics are given for many weeks to make children better. Often this doesn't stop the cough and antibiotics need to be injected into the child to treat the infection. Children have to take large amounts of antibiotics and have regular physiotherapy to help their cough. The only way to know if a child is better is when their parents report their cough has improved which is often unreliable. In this study we will take pictures of children's lungs using a type of scan called MRI, which is safe and does not expose children to radiation. Children breathe in a gas called xenon which fills the lungs. If there is phlegm blocking parts of the lungs, the gas cannot get through and we can see the blockage. This type of picture is the best way to measure early lung disease in children with other lung conditions such as cystic fibrosis and bronchiectasis. Measuring lung disease early will make children with PBBs lives better and mean they have to take less antibiotics. In some children, it will also help to stop lifelong lung diseases such as bronchiectasis.",[25],"Protracted Bacterial Bronchitis","RECRUITING","2026-04-29",{"date":29,"type":30},"2026-05-06","ACTUAL",{"date":32,"type":30},"2023-12-01",{"date":34,"type":21},"2026-05-31",{"name":36,"class":37},"Sheffield Children's NHS Foundation Trust","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":46,"targetDuration":48,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":38},"100612580","airway-microbiome-of-patients-with-protracted-bacterial-bronchitis-100612580","NCT07255430","Airway Microbiome of Patients With Protracted Bacterial Bronchitis","Interaction Between Microbiome, Virome and Host Immunity Response in the Context of Protracted Bacterial Bronchitis","Inclusion Criteria:\n\n* Children with PBB diagnosis according to case definition\n* Consent form signed by parents or legal guardians\n\nExclusion Criteria:\n\n* Comorbidities (HIV, asthma, chronic obstructive pulmonary disease, diabetes)\n* Have had serious illnesses (meningitis, pneumonia, bacteremia, empyema, etc) in the previous three months, identified only at the time of enrollment.\n* Have chronic respiratory conditions at the time of enrollment (non-PBB bronchiectasis not caused by PBB, CF, allergy, etc.).\n* Having received mechanical ventilation.\n* Having been hospitalized or used antibiotics in the previous three months at the time of enrollment.",{"count":47,"type":21},160,"12 Months","This project aims to assess the relationship between the microbiome and virome composition, the immune responses, and the respiratory health of children with protracted bacterial bronchitis (PBB). In addition, we aim to evaluate how the standard treatment with azithromycin interacts with the components of the microbiome, virome and immune biomarkers.",[25],[52,25,53],"cough","microbiome","2026-03-18",{"date":56,"type":30},"2026-03-19",{"date":58,"type":30},"2026-01-07",{"date":60,"type":21},"2029-01",{"name":62,"class":37},"University Hospital, Antwerp",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":38},"100621866","digital-physiotherapy-for-pediatric-chronic-suppurative-lung-diseases-100621866","NCT07376187","Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases","Digital Physiotherapy Services in the Management of Pediatric Chronic Suppurative Lung Diseases: A Randomized Controlled Trial","Inclusion Criteria\n\n* children aged 6 to 12 years old\n* clinically stable with an absence of pulmonary exacerbation four weeks prior to the study's recruitment\n* adherence to attend regular medical follow-up from a pediatric pulmonologist every three months\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* Immunodeficiency or asthma as their primary condition\n* Clinical evidence of cardiovascular, neuromuscular, metastatic, or psychiatric comorbidities, and neuromuscular or musculoskeletal impairments that affect mobility and the ability to follow instructions\n* Medical history of lung transplant\n* Participation in other rehabilitation programs, or attendance at regular physiotherapy ACTs sessions (\\>10 sessions in a 3-month period)\n* Lack access to the internet (e.g., no smartphone, tablet, or laptop)\n* Inability to use technological devices","6 Years","12 Years",{"count":73,"type":21},32,"INTERVENTIONAL",[76],"NA","This is a prospective, single-center, two-arm (1:1), assessor-blinded, randomized controlled clinical trial that will be conducted in collaboration with the outpatient clinic of the third Pediatric Pulmonology Unit, \"Attikon\" University Hospital of Athens in Greece. The aim of the study is to investigate the effects of applying digital physiotherapy services in the management of specific clinical outcomes in children with chronic suppurative lung diseases, other than cystic fibrosis. The research question is whether airway clearance techniques and exercise training that are performed remotely using digital health services (DHSs) can improve functional and exercise capacity, as well as compliance with ACTs, compared to usual care. The intervention program includes airway clearance techniques (ACTs), as well as aerobic and strengthening exercises that can be implemented easily in an online setting at home with minimal equipment. The duration of the program will be 12 weeks, and the prescribed weekly regimen will consist of 50-minute remote sessions: two synchronous, supervised sessions conducted via the Vsee platform, and a minimum of one asynchronous, unsupervised session. Children will be encouraged to maintain daily adherence to the exercise protocol.",[79,25,80,81],"Chronic Suppurative Lung Disease","Primary Ciliary Dyskinesia (PCD)","Non Cystic Fibrosis Bronchiectasis",[83,84,85,86,87,88],"chronic suppurative lung diseases","digital health services","pediatric","physiotherapy","remote","website","NOT_YET_RECRUITING","2026-01-28",{"date":92,"type":30},"2026-01-30",{"date":94,"type":21},"2026-05-01",{"date":96,"type":21},"2028-08-31",{"name":98,"class":37},"University of Thessaly",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100610820","biomarkers-and-respiratory-omics-as-new-children-opportunities---study-of-clinical-outcomes-and-predictivity-evaluation-100610820","NCT07232550","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation - a Multi-cohort, Multi-center Study","BRONCHOSCOPE","Inclusion Criteria:\n\n* Age at the beginning of the study 0-17 years old\n* Clinical indication and qualification by the attending physician for fiberoptic bronchoscopy under general anesthesia:\n\n  * Obstruction of the airways:\n  * Suspicion of foreign body aspiration\n  * Persistent stridor\n  * Abnormal result of functional tests of respiratory system - flattening of inspiratory or expiratory curve, presence of restriction (tested vital capacity \\\u003C5 percentile) or irreversible obstruction (persistence of Tiffneau index \\\u003C5 percentile despite administration of bronchodilators)\n  * Radiological findings located in the course of the larynx, trachea or bronchi\n  * Persistent atelectasis on subsequent radiological examinations\n  * Persistent cough \\>4 weeks\n  * Hemoptysis\n  * Suspected laryngomalacia or tracheobronchomalacia\n  * Suspected tracheoesophageal fistula\n  * Persistent dyspnea unresponsive to anti-asthmatic treatment used for min. 2 months, with no other identifiable causes\n  * Radiologically detected mediastinal abnormalities\n  * Suspected presence of a vascular ring\n  * Presence of excessive secretions that are impossible for the patient to expectorate\n  * Fine needle biopsy of cystic lesions\n* Obtained consent from patient\u002Flegal guardian for participation in the study\n\nExclusion Criteria:\n\n* Active acute respiratory infection up to 4 weeks before the procedure\n* Taking antibiotics or systemic glucocorticosteroids up to 4 weeks before the procedure\n* Patients with very severe comorbidities (congenital immunodeficiencies, genetic disorders, neurological or neuromuscular diseases, cancer, severe congenital heart defects, heart failure, liver failure, inflammatory bowel disease, celiac disease)\n* Patients with blood clotting disorders\n* Children with diagnosed respiratory diseases other than asthma and protracted bacterial bronchitis - including interstitial diseases, tuberculosis, inflammation of small and medium-sized blood vessels\n* Patients for whom \\>48 hours have passed between suspicion of foreign body aspiration and interventional bronchoscopy\n* Children with foreign body aspiration having a foreign body located in the trachea",{"count":47,"type":21},"The goal of this observational study is to improve the identification of biomarkers that predict disease progression and to assess the effectiveness of current therapies in children with asthma and protracted bacterial bronchitis.\n\nThe main aim of the study is to evaluate the microbiome composition and diversity, cellular composition, and metabolomic profile. In addition, to assess their correlation on subsequent treatment and disease course in children with asthma, protracted bacterial bronchitis, and in those receiving inhaled glucocorticosteroids without a diagnosis of asthma.\n\nParticipants will undergo fiberoptic bronchoscopy. During bronchoscopy, the performing physician will collect Bronchoalveolar lavage fluid samples for metagenomic and metabolomic analysis, as well as mucosal biopsies for histopathological evaluation.",[110,25,111],"Asthma in Children","Chronic Cough",[113,114],"PBB","Asthma","2025-11-14",{"date":117,"type":30},"2025-11-18",{"date":119,"type":21},"2025-11",{"date":121,"type":21},"2035-12",{"name":123,"class":37},"Medical University of Warsaw",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":16,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":74,"phases":137,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":157},"100517682","phase-4-antibiotics-microbiology-and-immunology-in-children-with-chronic-wet-cough---the-amic-study-100517682","NCT06020716","Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study","A Phase 4 Double Blinded Study With Two Different Interventions, Each With Two Arms, to Evaluate the Clinical Efficacy of Antibiotics and the Role of Microbiology, Immunology and Genetics in Children Aged 9-36 Months With Chronic Wet Cough.","AMIC","Inclusion Criteria:\n\n1. Age ≥ 9 and \\\u003C 36 months.\n2. Body weight ≥ 7 kg and \\\u003C 24 kg.\n3. Born term with Gestational age ≥ 37 weeks.\n4. Chronic wet cough for \\> 4 weeks at screening and in addition average cough score last 7 days at randomization ≥ 4 points and without signs of another cause. Registration ≥ 5 days is mandatory.\n5. Written informed consent obtained from both parents at inclusion.\n6. The study subject must be assessed as eligible for treatment with Augmentin.\n\nExclusion Criteria:\n\n1. Gestational age \\\u003C 37 weeks.\n2. History of acute upper or lower airway infection the last 2 weeks.\n3. History of other viral or bacterial infections the last 2 weeks.\n4. Episode with temperature above 38 °C during the last 2 weeks.\n5. Previous diagnosed with chronic lung disease such as cystic fibrosis, primary ciliary dyskinesia, interstitial lung disease, asthma, immunodeficiency, esophagus atresia.\n6. Cardiac disease, except persisting foramen ovale or ductus arteriosus.\n7. Severe feeding problems\u002Faspiration.\n8. Gastroesophageal reflux suspicion or confirmed by ph measurement.\n9. Suspicion of hypertrophic tonsils or adenoids\n10. Episodes of bronchopulmonary obstruction suggesting asthma\n11. Presence of gross neurodevelopmental delay, or suspicion of neurological disease.\n12. History of known or suspected allergic reactions to amoxicillin-clavulanate or any other betalactam.\n13. Episodes with haemoptysis and with unknown cause.\n14. Radiographic changes other than perihilar changes confirmed by x-ray at screening.\n15. At examination: Digital clubbing, hypoxia, chest wall deformity, dyspnoea at rest.\n16. Parents unable to speak and\u002For understand Norwegian language.\n17. Received systemic antibiotics within the last 6 months before inclusion.\n18. Participation in another clinical intervention trial.",true,"9 Months","36 Months",{"count":136,"type":21},350,[138],"PHASE4","The AMIC study is a double-blind, placebo-controlled, multicenter, nationwide, randomized controlled academic pharmaceutical trial.\n\nOVERALL PRIMARY OBJECTIVES:\n\n* To study the clinical efficacy of antibiotics in children with chronic wet cough (CWC).\n* To study if duration of treatment with antibiotics in children with CWC has impact on efficacy or time to relapse of symptoms.\n\nOVERALL SECONDARY OBJECTIVE:\n\n-To study respiratory pathogens and the diversity\u002Fcomposition of airway and gut microbiome in children with CWC compared to healthy controls, and changes in pathogens\u002Fmicrobiome after treatment with antibiotics.\n\nOVERALL TERTIARY OBJECTIVE:\n\n-To study the role of inflammation, immunology, and genetics in children with chronic wet cough and suspicion of PBB to increase the knowledge of pathophysiological mechanisms associated with PBB.\n\nThe study will include two different RCTs AMIC 1 and AMIC 2:\n\nAMIC 1:\n\nParticipants will be randomly assigned to 14 days amoxicillin-clavulanate syrup or placebo.\n\nAMIC 2:\n\nParticipants will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup.",[25],[142,143,144,145,146],"Chronic wet cough","Antibiotic","Children","Microbiology","Immunology","2024-12-20",{"date":149,"type":30},"2024-12-27",{"date":151,"type":30},"2023-08-16",{"date":153,"type":21},"2028-04-30",{"name":155,"class":156},"Helse Stavanger HF","OTHER_GOV",7]